Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Sernova — Investor Presentation (May 2020)
33 slides from Sernova Biotherapeutics's investor presentation, May 2020

Slide 1: The Path To A Regenerative Medicine Cure
SEOVF TRADED ON The Path To A Regenerative Medicine Cure Corporate Presentation May 2020

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expects

Slide 3: Regenerative Medicine - The Future Now
Regenerative Medicine - The Future Now Regenerative Medicine (RM) is a rapidly evolving field of science developing new therapeutic solutions to treat disease: with the repair or growth of new tissues & organs, i.e. organ regeneration repairing cells at the gene level to prevent disease, i.e. ge

Slide 4: Sernova: Innovator & Leader
Sernova: Innovator & Leader Publicly traded, clinical-stage RM therapeutics solution innovator & leader: Cell therapy therapeutics solution platform treating chronic diseases & enhancing daily QOL Integrated RM therapeutic solution (implantable Cell Pouch™ device + immune-protected therapeutic c

Slide 5: Sernova's Platform Approach
Sernova's Platform Approach Integrated RM Therapeutic Solution for 28% 40% Treatment of Chronic Diseases 32% Cell Pouch Therapeutic Cells Immune Protection Implantable proprietary medical Human cells (donor / stem) & Technologies to protect device that provides vascularized tissues that produce & re

Slide 6: Worldwide IP / Patent Portfolio
Worldwide IP / Patent Portfolio International patents & patent applications portfolio in multiple patent families with broad application & continued expansion: Composition & use of medical devices for delivery & cell transplantation Glucose responsive insulin secreting stem cell technologies L

Slide 7: Diabetes … Finally Hope for a Functional Cure
Diabetes … Finally Hope for a Functional Cure The Reality: Diabetes is one of the most prevalent diseases & pervasive medical problems impacting society & everyday quality of life (QOL) today 463 million affected worldwide and nearly 10% of these individuals have T1D(1) T1D represents a potentia

Slide 8: Sernova Pipeline
Sernova Pipeline CELL POUCH PRE- DEVELOPMENT CANDIDATE CLINICAL PHASE I PHASE II PHASE III STAGE INDICATION HUMAN DONOR ISLETS, P H A S E I /I I I N I T I AT E D HYPOGLYCEMIA SYSTEMIC IMMUNE DEC 2018 UNAWARENESS PROTECTION T1D A N T I C I PAT E D 2 ND ALL INSULIN LOCALLY IMMUNE- A P P R O VA L F O R

Slide 9: Diabetes Market Opportunities for Sernova
Diabetes Market Opportunities for Sernova IP Status 2020 Potential Patient Population Potential Commercial Opportunity (before market access considerations) T1D Severe HU T1D Severe HU Device / Method T1D Severe HU All T1D T1D Severe HU All T1D with Human with Human Patent with iPSC with iPSC with i

Slide 10: RM Diabetes Competitive Landscape
RM Diabetes Competitive Landscape Clinical Efficacy Data: Device Vascularization Local Immune Financial Metrics Therapeutic C-peptide Levels Islet Engraftment Protection Technology (USD Millions) Measured in Bloodstream Demonstrated in Humans Phase I/II initiated late 2018 in T1D Interim data demons

Slide 11: Cell Pouch Solves Device Conundrum
Cell Pouch Solves Device Conundrum The Device Conundrum “We thought the cells would be the hard part and focused our efforts there. It’s obvious now having a functional device will be the limiting factor and there are few current options.” Big Pharma executive 2020 JPM comment The challenging device

Slide 12: Therapeutic Cells
Therapeutic Cells Therapeutic Cell Options Human donor cells enable early safety / efficacy testing in the clinic for indications & patients with unmet needs & advanced disease (i.e. diabetes HU patients). Supply is limited; however, they enable Cell Pouch validation in preparation for stem cell t

Slide 13: Immune Protection
Immune Protection Transplanted therapeutic cells must be protected from a natural immune system attack response. While established systemic transplantation immuno-suppression (anti-rejection) drugs can be effective, local immune protection (LIP) is optimal. LIP alternatives present different opp

Slide 14: Biologically Compatible Delivery Process
Biologically Compatible Delivery Process Cell Pouch Implantation & Therapeutic Cells Delivery Process Proprietary Cell Pouch is Therapeutics cells are Therapeutic cells release placed deep under the skin, transplanted directly into the missing proteins or allowing for vascularization & vascularized

Slide 15: Strategic Development Approach
Strategic Development Approach Device Therapeutic Immune Sernova Integrated Cells Protection RM Therapeutic Solution Immuno Portfolio Human Suppression Drugs Cell Therapeutic Donor (systemic) Pouch Cells Sernova Stem Cell Cell Encapsulation Proprietary Derived Conformal Coating Cell Pouch (iPSC / EP

Slide 16: Diabetes Clinical Progress Summary
Diabetes Clinical Progress Summary Completion of first-in-human proof-of-concept study for diabetic condition HU Clinical protocol & regulatory package development for US Ph I / II clinical trial for Pre 2018 diabetic HU condition (T1D Study) FDA IND clearance to commence T1D Study T1D Study

Slide 17: T1D First Clinical Indication: HU
T1D First Clinical Indication: HU Hypoglycemia Hypoglycemia unawareness unawareness (HU), the(HU), most the most critical critical unmet needunmet needaffects in diabetes, in diabetes, 15% of T1D affects patients 15% (~240K of T1Dinpatients patients (~240 K patients in the US alone) the US alone)

Slide 18: US Ph I/II Study Design
US Ph I/II Study Design US Ph I/II Safety, Tolerability, Efficacy Study Study Design: Company-sponsored IND. Open-label, single-arm study. Human donor islets are transplanted into the Cell Pouch after implantation & stable anti-rejection medication activity has been established. Primary Objective: T

Slide 19: US Ph I/II Study Design
US Ph I/II Study Design US Ph I/II Safety, Tolerability, Efficacy Study Immuno Secondary Endpoints: Suppression Survival of Endocrine Tissue & Identification of Hormones Introduced Small Reduction in hypoglycemic events (sentinel) Reduction in HbA1c Pouches Cell 1st Islet Dose Removed Pouch™ Transpl

Slide 20: US Ph I/II: Case Study Early Findings
US Ph I/II: Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study Safety Findings (90 days post-transplant) Incidence & severity of adverse events associated with Cell Pouch were monitored: No incidences of AEs determined to be probable or highly probable to the Cell Pouch Ce

Slide 21: US Ph I/II: Case Study Early Findings
US Ph I/II: Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study First Patient Observed Data Presented by Clinical Investigator* Early Efficacy Findings Islet Transplant Status: Before 3 Mo. After 90-day post-transplant glucose tolerance test (i.e. patient given a high sugar dri

Slide 22: US Ph I/II: Case Study Early Findings
US Ph I/II: Case Study Early Findings Improvement in ALL CGM Parameters Blood Glucose Over Time (mg/dL) Baseline: More excursions seen pre-transplant Parameter Baseline Post-transplant (90 days) High Glucose Value (mg/dL) 285 231 Low Glucose Value (mg/dL) 50 66* # Glucose Excursions 15 3 # High Excu

Slide 23: US Ph I/II: 90-Days Post Transplant
US Ph I/II: 90-Days Post Transplant Achievement of Secondary Endpoint “Survival of endocrine tissue in the Cell Pouch™ (defined by positive staining of islets during histological analysis) [ Time Frame: 90±5 days post-transplant for sentinel Cell Pouch™ ]” Islets Independent Pathologist reported:

Slide 24: Earlier First-in-Human Study
Earlier First-in-Human Study First-in-World Successful Proof-of-Concept Study Design T1D subjects with HU & a history of severe hypoglycemic episodes Open-label, single-arm Donor islet transplantation 2 – 24 weeks post Cell Pouch implantation Primary Endpoint: Safety post Cell Pouch implanta

Slide 25: T1D Data: Pre-Clinical Studies
T1D Data: Pre-Clinical Studies Clinical Studies Human Study #2: US Ph I/II Safety, Human Study #1: First-in-Human Study #2: US Ph I/II Safety, Tolerability, Efficacy Study Proof-of-Concept Tolerability, 2019 • Conducted in conjunction with the University of • Conducted in conjunction with Health Can

Slide 26: Cell Pouch – A Durable Cell Environment
Cell Pouch – A Durable Cell Environment Long-Term Vascularized Tissue Chamber Development Proven Across All Pre-Clinical 1) Animal Models, 2) Implant Sites & 3) Disease Models 1 2 3H&E 1.7x Non-Transplanted Cell Pouch Hemophilia A Mouse Abdomen mouse model Model (NHP) Sernova Confidential SH1-P047 N

Slide 27: Pre-Clinical Diabetes Model Efficacy
Pre-Clinical Diabetes Model Efficacy Pre-Clinical Porcine Large Animal Cell Pouch Study Cell Pouch Implant Pancreatectomy Diabetes Islet Transplant Cell Pouch Removal Induction (STZ) 4-8 weeks 1 day 4-7 days 8-12 weeks 1 week Insulin Insulin 12 Weeks Post Cell Pouch Nuclei Glucagon WHY IS THIS and I

Slide 28: Hemophilia A Program
Hemophilia A Program Estimated ~20 K patients across North America & EU Market ~$10 B orphan indication Benefits of Sernova’s Cell Pouch with factor VIII releasing cells: Patients receive regular infusions of missing Standard clotting factors (i.e. factor VIII) Reduce / eliminate factor of C

Slide 29: Hemophilia A Program: Pre-Clinical Success
Hemophilia A Program: Pre-Clinical Success Pre-Clinical Safety & Efficacy of Hemophilia Cell Therapy in the Cell Pouch Confirmed Release-tested HLA-ABC BOECs FVIII DAPI Human stained (red) 40x Cell Pouch Transplanted with Cells Human corrected Human factor VIII BOECs transplanted corrected blood 40×

Slide 30: Thyroid Disease Program
Thyroid Disease Program Estimated 150,000 thyroidectomies performed annually in US ~$2.2 B market opportunity Market Benefits of Sernova’s Cell Pouch with Thyroid releasing cells: Patients require lifelong thyroid hormone Reduce / eliminate daily life replacement therapy Standard long thyroi

Slide 31: Thyroid Program: Pre-Clinical Success
Thyroid Program: Pre-Clinical Success Pre-Clinical Safety & Efficacy of the Thyroid Tissue Therapy in the Cell Pouch Human Thyroid Tissue Surviving Human Thyroid Tissue in Cell Pouch in mouse model ( 3 months post-transplant) Cell Pouch Transplanted with Healthy Human TG (green) TPO (red) Thyroid Ti

Slide 32: NEXT STEPS - 2020 Action Plan
NEXT STEPS - 2020 Action Plan Acquire or license local immune-protection technologies for therapeutic cells Platform Advance local immune-protected diabetes stem cell technology in preparation Technology for First-in-Man (FIM) study Expand existing strong worldwide multi-family patent portfoli

Slide 33: 700 Collip Circle, Suite 114 London, Ontario Canada
700 Collip Circle, Suite 114 London, Ontario Canada N6G 4X8 (519) 858-5126 info@sernova.com www.sernova.com
Source: Internet Archive copy of sernova.com
More decks from Sernova Biotherapeutics Inc
Merger or Acquisition (2026)16 slides · 2026
Investor Presentation (February 2025)24 slides · February 2025
Investor Presentation (December 2024)31 slides · December 2024
Investor Presentation (September 2024)21 slides · Sep 12, 2024
Investor Presentation (March 2024)32 slides · March 2024
Sernova — Investor Presentation (September 2023)27 slides · September 2023